Novo Nordisk A/S (NYSE:NVO) Given Consensus Rating of "Moderate Buy" by Brokerages

Novo Nordisk A/S (NYSE:NVO - Get Free Report) has earned an average rating of "Moderate Buy" from the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $145.25.

NVO has been the topic of a number of analyst reports. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. BMO Capital Markets decreased their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research note on Monday, December 23rd. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. Finally, Morgan Stanley started coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. GQG Partners LLC increased its stake in shares of Novo Nordisk A/S by 74.7% during the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after acquiring an additional 5,556,460 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $404,910,000. Loomis Sayles & Co. L P grew its stake in shares of Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after purchasing an additional 2,947,771 shares during the period. Nuveen Asset Management LLC increased its holdings in shares of Novo Nordisk A/S by 73.2% in the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after purchasing an additional 2,639,693 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $158,657,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Remove Ads

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded down $1.55 during mid-day trading on Monday, reaching $70.18. The company's stock had a trading volume of 7,960,074 shares, compared to its average volume of 5,475,688. The stock has a 50-day moving average of $82.78 and a two-hundred day moving average of $99.75. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The stock has a market capitalization of $314.93 billion, a P/E ratio of 21.33, a P/E/G ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 1-year low of $69.78 and a 1-year high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a dividend yield of 1.2%. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S's payout ratio is presently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.